.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

UBS
Healthtrust
Citi
Medtronic
AstraZeneca
Accenture
US Department of Justice
Queensland Health
Cantor Fitzgerald
Daiichi Sankyo

Generated: December 16, 2017

DrugPatentWatch Database Preview

VIBERZI Drug Profile

« Back to Dashboard

Which patents cover Viberzi, and when can generic versions of Viberzi launch?

Viberzi is a drug marketed by Allergan Holdings and is included in one NDA. There are twelve patents protecting this drug.

This drug has one hundred and fourteen patent family members in thirty-five countries and six supplementary protection certificates in five countries.

The generic ingredient in VIBERZI is eluxadoline. One supplier is listed for this compound. Additional details are available on the eluxadoline profile page.

Summary for VIBERZI

Drug patent expirations by year for VIBERZI

Pharmacology for VIBERZI

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan HoldingsVIBERZIeluxadolineTABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Allergan HoldingsVIBERZIeluxadolineTABLET;ORAL206940-001May 27, 2015RXYesNo► Subscribe► SubscribeYY► Subscribe
Allergan HoldingsVIBERZIeluxadolineTABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
Allergan HoldingsVIBERZIeluxadolineTABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Allergan HoldingsVIBERZIeluxadolineTABLET;ORAL206940-001May 27, 2015RXYesNo► Subscribe► SubscribeY► Subscribe
Allergan HoldingsVIBERZIeluxadolineTABLET;ORAL206940-001May 27, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Allergan HoldingsVIBERZIeluxadolineTABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
Allergan HoldingsVIBERZIeluxadolineTABLET;ORAL206940-001May 27, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Allergan HoldingsVIBERZIeluxadolineTABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
Allergan HoldingsVIBERZIeluxadolineTABLET;ORAL206940-002May 27, 2015RXYesYes► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: VIBERZI

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,994,206Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid► Subscribe
8,859,604Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid► Subscribe
8,609,865Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VIBERZI

Country Document Number Estimated Expiration
New Zealand582420► Subscribe
Serbia52933► Subscribe
Serbia51995► Subscribe
Serbia54199► Subscribe
Singapore185941► Subscribe
European Patent Office2298744► Subscribe
Serbia55122► Subscribe
CroatiaP20110694► Subscribe
Portugal2653465► Subscribe
Slovenia1725537► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VIBERZI

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90007-7Sweden► SubscribePRODUCT NAME: ELUXADOLINE OR A PHARMACEUTICALLY ACCEPTABLE ENANTIOMER, DIASTEREOMER, RACEMATE OR SALT THEREOF; REG. NO/DATE: EU/1/16/1126 20160921
2017000010Germany► SubscribePRODUCT NAME: ELUXADOLIN; REGISTRATION NO/DATE: EU/1/16/1126 20160919
0865Netherlands► SubscribePRODUCT NAME: ELUXADOLINE OF EEN FARMACEUTISCH AANVAARDBAAR ENANTIOMEER,DIASTEREOMEER, RACEMAAT OF ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/16/1126 20160921
2017005Lithuania► SubscribePRODUCT NAME: ELUKSADOLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINAS ENANTIOMERAS, DIASTEREOMERAS, RACEMATAS ARBA DRUSKA; REGISTRATION NO/DATE: EU/1/16/1126 20160919
2017 00008Denmark► SubscribePRODUCT NAME: ELUXADOLIN ELLER EN FARMACEUTISK ACCEPTABEL ENANTIOMER, DIASTEREOMER, RACEMAT ELLER SALT DERAF; REG. NO/DATE: EU/1/16/1126 20160921
2017000009Germany► SubscribePRODUCT NAME: ELUXADOLIN ODER EIN PHARMAZEUTISCH AKZEPTABLES ENANTIOMER, DIASTEREOMER, RACEMATE ODER SALZ DAVON; REGISTRATION NO/DATE: EU/1/16/1126 20160919
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Harvard Business School
Dow
Deloitte
Baxter
UBS
AstraZeneca
Express Scripts
US Army
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot